VC  MPM Capital

http://www.mpmcapital.com





     Office Locations:

601 Gateway Boulevard, Suite 350
South San Francisco, CA 94080
Phone: 650-553-3300
Fax: 650-553-3301

Get all office locations for this firm with a National Database subscription or Silicon Valley Database subscription.
 

Stages:

  • Early
  • Expansion
  • Growth
  • Seed


 

Industries:

  • Life Sciences & Healthcare
  • Medical Device

  •  

    Description:

    With over $2 billion under management, MPM invests in biotechnology, specialty pharma, medical technology, and related companies that provide innovative medical products and requisite services to the healthcare industry, irrespective of geography, stage of development and therapeutic area. MPM Capital closed its fifth venture initiative, the MPM BioVentures V family of funds ('BV5') in 2010. With committed capital just under $300 million, BV5 has a portfolio of 6 companies currently. MPM is actively building the BV5 portfolio and is seeking innovative healthcare opportunities in the U.S. and abroad. In May of 2016, the firm launched a social impact oncology fund, raised in partnership with UBS. The UBS Oncology Impact Fund, with $471 million in committed capital, is an evergreen, crossover fund dedicated to investing in cancer therapeutics. Twenty percent of the committed capital will be dedicated to public equity investments, and the balance to private companies.



    Investment Firm Key

       VC = Venture Capital
       PE = Private Equity
       A = Angel
       I = Incubator
       MB = Merchant Bank
       VD = Venture Debt
       FI = Family Investment Office
       FOF = Fund of Funds
       ED = Economic Development Office   
       TT = Technology Transfer Office
       CVC = Corporate Venture Capital
       SEC = Secondary Purchaser
       HF = Hedge Fund/Mutual Fund
       
       
       
    COMPANY STAGEREVENUE
    Venture Capital
    Seed Stage
    (includes "pre-seed," or
    concept stage)
    No Revenue
    Early StageMinimal
    Revenue
    Growth Stage
    (also called Mid-stage)
    $2M-$7M
    Expansion Stage
    (also called Late-stage)
    $7M and greater
    Private Equity
    Lower Middle Market$10M-$249M
    Middle Market$250M-$499M
    Upper Middle Market$500M-$1B
    Large Cap>$1B
       
       
     

    Investment Team:


    Name   Title
    Get the complete investment team + individual email addresses for investment team partners. Get personal images, LinkedIn links, investment specialties, office locations and more with a National Database subscription or Silicon Valley Database subscription.
    Ansbert Gadicke MD Managing Director
    Bard Geesaman MD, PhD Managing Director
    Carl Weissman Venture Partner
    Dan Hicklin PhD Managing Director
    David Stack Managing Director

     

    Recent Funding Events (trailing 12 months):


      Date


      Name


      State


      Amount


      Stage


      11/30/2017


      Semma Therapeutics


      MA


      $114,000,000


      Series B


      10/18/2017


      Blade Therapeutics


      CA


      $45,000,000


      Series B


      10/03/2017


      Cullinan Oncology


      MA


      $150,000,000


      Series A


      06/22/2017


      Repare Therapeutics


      MA


      $68,000,000


      Series A


      05/25/2017


      Harpoon Therapeutics


      CA


      $45,000,000


      Series B


      02/17/2017


      Rhythm


      MA


      $41,000,000


      Mezzanine


     

    Portfolio companies include:


      23andMe
        web link


      Aires Pharmaceuticals
        web link


      Allozyne
        web link


      Anthera Pharmaceuticals
        web link


      Aratana Therapeutics
        web link


      Aratanaapeutics
        web link


      Astute Medical
        web link


      AVEO Pharmaceuticals
        web link


      Barrier Therapeutics
        web link


      Blade Therapeutics
        web link


      Cardiac Dimensions
        web link


      Celladon
        web link


      Cerecor
        web link


      Ceregene
        web link


      Chiasma
        web link


      Clinical Ink
        web link


      Colucid Pharmaceuticals
        web link


      Conatus Pharmaceuticals
        web link


      Critical Therapeutics
        web link


      Cullinan Oncology
        web link


      Dragonfly Sciences
        web link


      EKR Holdings
        web link


      Elixir
        web link


      EndoGastric Solutions
        web link


      EnteroMedics
        web link


      Epigenomics
        web link


      Epizyme
        web link


      ForteBio
        web link


      Harpoon Therapeutics
        web link


      Iconic Therapeutics
        web link


      Idenix Pharmaceuticals
        web link


      iPeirian
        web link


      Kalidex
        web link


      KaloBios Pharmaceuticals
        web link


      MacroGenics
        web link


      NeoVista
        web link


      NeuroTherapeutics Pharma
        web link


      Nevro
        web link


      Oncorus
        web link


      Oxagen
        web link


      Pacira Pharmaceuticals
        web link


      Peptimmune
        web link


      PrimeraDx
        web link


      Proteon Therapeutics
        web link


      QuatRx Pharmaceuticals
        web link


      Radius Health
        web link


      Raze Therapeutics
        web link


      Repare Therapeutics
        web link


      Rhythm
        web link


      Rhythm Pharmaceuticals
        web link


      Selexys Pharmaceuticals
        web link


      Semma Therapeutics
        web link


      Sideris Pharmaceuticals
        web link


      Surface Logix


      Syndax Pharmaceuticals
        web link


      Theraclone Sciences
        web link


      Tizona Therapeutics
        web link


      TriVascular
        web link


      True North Therapeutics
        web link


      Valeritas
        web link


      Vascular Pharmaceuticals
        web link


      Verastem
        web link


      Xanodyne Pharmaceuticals


     

    Recent News: